Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
about
SYK is a critical regulator of FLT3 in acute myeloid leukemiaTargeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidenceFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaThe Future of Targeting FLT3 Activation in AML.Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Is targeted therapy feasible in acute myelogenous leukemia?CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationTargeted drug discovery for pediatric leukemia.Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation.FLT3 inhibitors: clinical potential in acute myeloid leukemia.FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.The role of quizartinib in the treatment of acute myeloid leukemia.FLT3 inhibitors in AML: are we there yet?The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.Targeting FLT3 to treat leukemia.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Targeting the microenvironment in acute myeloid leukemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinaseUse of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.Advances in targeted therapy for acute myeloid leukaemia.The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
P2860
Q24337247-A88E24D9-6439-44A3-BA12-8B1F2BFC4480Q26770388-EFD6F298-8E06-4912-85A3-DC757BF3EEF9Q27028163-8154264C-6D1A-4988-ACC9-4BE087DBC213Q33442949-08881CEF-B44B-491F-815B-98506037A259Q33767026-620DAB9F-EE60-4676-82CB-523B238107A4Q33943277-FE542128-6A4B-499E-A383-402E75047831Q34555386-0765E8AB-ECB7-4606-81CB-ABD8968C2FC6Q35688721-0B4EE4AC-6B8B-4840-BAFA-80E0B3915DF0Q36276942-121B4EA5-9634-4B1B-A4AA-1073EAFF33D7Q36416358-D8E924AE-E521-4D93-93D0-123DC636EE50Q36545966-70C66F5A-DB3E-421C-9C44-D2E3C8385789Q36907832-9A9F588A-E4F5-4D9D-B341-6D6362C0E160Q36989223-59D533DB-A35F-49AA-B30B-BC0762339318Q37052890-0EE304E7-CE5E-45EC-A33A-DFDCCD705D0AQ37361836-561E24AA-5850-4361-B85F-3EEDE831FE81Q37638749-9D508540-3E6D-4CC3-9F78-8F67C476DD58Q38101284-BDA5CE3E-B43F-43F2-A779-BF68B056B841Q38144189-74925B93-5538-437F-BEDF-A229FF96AF7AQ38200564-550ADB98-A073-4EF4-BABC-0DA536CF2089Q38216649-9C85FE02-D70C-422C-A485-BDEE0C9D80BEQ38241988-002996D6-4B24-4280-B6F4-681616891AA8Q38251339-53C805AF-0CDF-4E60-BCBF-64756CEC7700Q38428692-0CAAF0F6-4C21-45E3-852B-1CB973FF6015Q38447268-211882F2-631E-4339-B972-46AA92A3FE6BQ38664735-4F892926-85DB-440A-81A4-FDD0736E9E31Q38810393-8C047147-3C2E-44FE-B33C-0065EAE10845Q39142229-BBA577F4-C27F-49E4-A86D-39220CFB6920Q39411949-2F978915-D7D3-45E8-98B9-D751E5850438Q40103401-4E4B2E4F-F949-40B3-BE5A-85F9A3B11B5EQ40832501-6E1CED75-6A67-4532-95F6-0671DA5650CBQ41549311-19095B0A-754F-4356-8CE3-D0EA95A08D8AQ42979880-8AD30213-343D-48D1-B092-695DF6DC01A1Q43070849-008C951B-B9D8-406D-A58A-791C6A7275E1Q47142820-320F7BFD-11AA-4248-9EA6-7661A48802BEQ47326031-938757EA-E962-4C7D-9504-E2AE5A9A23D3Q47561019-26D78D09-CEE3-4718-9CAC-79FB53BFA44EQ47797184-5619701F-64FE-4859-8ABD-56EB4D0E14C9Q48204144-E0E9EA8F-B773-4BCE-8A2A-8545EF7EE6BCQ48371869-83C42D97-D38D-4BC5-9F90-C12399981FB7Q50921811-93ECCACC-9BE3-426F-8337-AFA01D80D217
P2860
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
@ast
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
@en
type
label
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
@ast
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
@en
prefLabel
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
@ast
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
@en
P2093
P2860
P1433
P1476
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
@en
P2093
Alexander Perl
Amy Sexauer
B Douglas Smith
Christopher Gocke
Grant E Nybakken
Judith Karp
Keith Pratz
Mark Frattini
Mark Levis
Michael Borowitz
P2860
P304
P356
10.1182/BLOOD-2012-01-402545
P407
P577
2012-09-25T00:00:00Z